| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +7.1% | $234,944,605 | +$58,553,941 | 5,970,638 | +33% | FMR LLC | 30 Sep 2025 |
| Point72 Asset Management, L.P. | 6.9% | +32% | $107,936,599 | +$31,151,331 | 2,981,674 | +41% | Point72 Asset Management, L.P. | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 6% | -35% | $94,544,735 | -$45,431,000 | 2,611,733 | -32% | RA Capital Management, L.P. | 31 Dec 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 6.5% | $101,431,000 | 2,577,662 | Wellington Management Group LLP | 30 Sep 2025 | |||
| Octagon Capital Advisors LP | 6.1% | -14% | $95,095,846 | +$12,060,775 | 2,416,667 | +15% | Octagon Capital Advisors LP | 30 Sep 2025 |
| Fairmount Funds Management LLC | 4.9% | -50% | $72,191,285 | -$64,524,950 | 2,139,635 | -47% | Fairmount Funds Management LLC | 21 Nov 2025 |
| Avidity Partners Management LP | 4.9% | -50% | $70,995,168 | -$43,010,234 | 2,104,184 | -38% | Avidity Partners Management LP | 17 Nov 2025 |
| BlackRock, Inc. | 5% | $34,803,328 | 1,600,153 | BlackRock, Inc. | 31 Mar 2025 | |||
| TCG Crossover GP II, LLC | 4.7% | $32,660,322 | 1,501,624 | TCG Crossover GP II, LLC | 31 Mar 2025 | |||
| BCLS Fund III Investments, LP | 3.1% | -55% | $51,780,350 | -$45,896,187 | 1,315,892 | -47% | BCLS Fund III Investments, LP | 30 Sep 2025 |
| Vestal Point Capital, LP | 3% | -70% | $46,433,000 | -$79,487,000 | 1,180,000 | -63% | Vestal Point Capital, LP | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 3.1% | $20,060,000 | 1,000,000 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 |
As of 31 Dec 2025, 166 institutional investors reported holding 49,120,530 shares of Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share (DNTH). This represents 114% of the company’s total 43,212,667 outstanding shares.
The largest institutional shareholders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, par value $0.001 per share (DNTH) together control 86% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 6,431,329 | +7.7% | 0.01% | $265,035,068 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.8% | 2,503,190 | -2.9% | 0.02% | $103,156,459 |
| Octagon Capital Advisors LP | 5.6% | 2,416,667 | 0% | 12% | $99,590,847 |
| Fairmount Funds Management LLC | 4.9% | 2,137,191 | -35% | 6.7% | $88,073,641 |
| Avidity Partners Management LP | 4.9% | 2,104,184 | -34% | 25% | $86,713,423 |
| VANGUARD GROUP INC | 4.7% | 2,048,452 | +25% | 0% | $84,416,707 |
| BlackRock, Inc. | 4.4% | 1,915,236 | +43% | 0% | $78,926,876 |
| TCG Crossover Management, LLC | 3.9% | 1,676,624 | 0% | 2.3% | $69,093,675 |
| RA CAPITAL MANAGEMENT, L.P. | 3.7% | 1,611,733 | -44% | 0.68% | $66,419,517 |
| STATE STREET CORP | 3.5% | 1,507,619 | +125% | 0% | $62,128,979 |
| BRAIDWELL LP | 2.9% | 1,273,935 | +53% | 1.7% | $52,498,861 |
| Point72 Asset Management, L.P. | 2.7% | 1,166,088 | -43% | 0.08% | $48,054,486 |
| CITADEL ADVISORS LLC | 2.5% | 1,068,934 | +5.5% | 0.03% | $44,050,770 |
| MARSHALL WACE, LLP | 2.3% | 1,008,533 | +76% | 0.04% | $41,561,643 |
| Polar Capital Holdings Plc | 2.3% | 1,004,728 | +34% | 0.19% | $41,404,841 |
| VR ADVISER, LLC | 2.3% | 1,000,000 | +4.1% | 2% | $41,210,000 |
| ALLIANCEBERNSTEIN L.P. | 1.9% | 834,383 | -2.1% | 0.01% | $34,384,923 |
| BAKER BROS. ADVISORS LP | 1.8% | 789,759 | 0% | 0.19% | $32,545,968 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.7% | 750,136 | +11% | 4.5% | $30,913,105 |
| Bain Capital Life Sciences Investors, LLC | 1.7% | 743,592 | -43% | 2.3% | $30,643,426 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 676,658 | +26% | 0% | $27,890,189 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 667,216 | +356% | 0.02% | $27,495,971 |
| Catalio Capital Management, LP | 1.5% | 653,572 | -2.1% | 5% | $26,933,702 |
| Tri Locum Partners LP | 1.4% | 622,403 | +240% | 3.3% | $25,649,228 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 616,033 | +185% | 0% | $25,388,000 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 49,120,530 | $2,024,265,201 | +$67,632,044 | $41.21 | 166 |
| 2025 Q3 | 46,828,772 | $1,842,663,442 | +$358,133,968 | $39.35 | 140 |
| 2025 Q2 | 39,106,709 | $728,558,630 | +$24,440,177 | $18.63 | 101 |
| 2025 Q1 | 37,715,319 | $685,461,303 | +$43,246,773 | $18.14 | 97 |
| 2024 Q4 | 35,126,689 | $765,706,199 | +$63,092,353 | $21.80 | 94 |
| 2024 Q3 | 31,364,805 | $858,714,506 | +$44,837,092 | $27.38 | 90 |
| 2024 Q2 | 29,702,499 | $768,778,734 | +$87,583,327 | $25.88 | 74 |
| 2024 Q1 | 26,075,021 | $782,250,559 | +$479,966,613 | $30.00 | 75 |
| 2023 Q4 | 10,291,119 | $106,507,945 | +$518,588 | $10.40 | 38 |
| 2023 Q3 | 10,072,640 | $136,328,208 | +$136,328,208 | $13.67 | 30 |